Future of Primary Care: Fewer Traditional Reps, Alternate Channels To Docs
Executive Summary
As U.S. pharmaceutical companies continue to adjust to dramatic changes in their operating environment, the traditional primary care detail rep will become extinct in five to seven years, Bain & Co. consultant Charles Farkas predicts
You may also be interested in...
Actelion Follows Innovation into GP Markets
Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.
Actelion Follows Innovation into GP Markets
Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.
As Pharma Downsizes Its Sales Reps, A CSO Becomes More Flexible
As pharmaceutical companies reorganize their commercial operations, contract sales organizations are accelerating efforts to carve out new roles to meet industry needs